Serina Therapeutics Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
SER
- Investments
-
1
- Share Price
-
$1.39
- (As of Friday Closing)
Serina Therapeutics General Information
Description
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Contact Information
Website
www.serinatx.comCorporate Office
- 601 Genome Way
- Suite 2001
- Huntsville, AL 35806
- United States
Corporate Office
- 601 Genome Way
- Suite 2001
- Huntsville, AL 35806
- United States
Serina Therapeutics Timeline
Serina Therapeutics Stock Performance
As of 13-Nov-2026, Serina Therapeutics’s stock price is $1.39. Its current market cap is $36.9M with 26.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.39 | $1.41 | $1.14 - $4.26 | $36.9M | 26.6M | 72.3K | -$1.63 |
Serina Therapeutics Financials Summary
As of 30-Sep-2026, Serina Therapeutics has a trailing 12-month revenue of $125K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 30,986 | 17,869 | 55,282 | |
| Revenue | 125 | 0 | 0 | 3,000 |
| EBITDA | (23,605) | (18,911) | (10,487) | 5,927 |
| Net Income | (24,496) | (19,182) | (11,141) | 5,269 |
| Total Assets | 21,873 | 6,951 | 6,724 | 8,968 |
| Total Debt | 3,370 | 3,142 | 268 | 3,445 |
Serina Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Serina Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Serina Therapeutics Comparisons
Industry
Financing
Details
Serina Therapeutics Competitors (60)
One of Serina Therapeutics’s 60 competitors is BeOne Medicines, a Formerly PE-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Hansa Biopharma | Corporation | Lund, Sweden | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | ||||
| GT Biopharma | Corporation | San Francisco, CA |
Serina Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Serina Therapeutics Patents
Serina Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260283956-A1 | Cationic poly(oxazoline) lipid conjugates and lipid nanoparticles and polyplexes including same | Pending | 24-Mar-2025 | ||
| WO-2026206901-A1 | Cationic poly(oxazoline) lipid conjugates and lipid nanoparticles and polyplexes including same | Pending | 24-Mar-2025 | ||
| US-20260216356-A1 | Polyoxazoline antibody-drug conjugates and methods of use | Pending | 29-Jan-2025 | ||
| WO-2026165233-A1 | Polyoxazoline antibody-drug conjugates and methods of use | Pending | 29-Jan-2025 | ||
| US-20250352664-A1 | Meth0ds of administering lipid nanoparticles including poly(ethyloxazoline)-lipid conjugates without raising immune response to polymer | Pending | 29-Jul-2024 | A61K47/6911 |
Serina Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Serina Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Serina Therapeutics Acquisitions (1)
Serina Therapeutics’s most recent deal was a Merger/Acquisition with AgeX Therapeutics. The deal was made on 26-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AgeX Therapeutics | 26-Mar-2024 | Merger/Acquisition | Drug Discovery |
Serina Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Serina Therapeutics FAQs
-
When was Serina Therapeutics founded?
Serina Therapeutics was founded in 2006.
-
Where is Serina Therapeutics headquartered?
Serina Therapeutics is headquartered in Huntsville, AL.
-
What is the size of Serina Therapeutics?
Serina Therapeutics has 16 total employees.
-
What industry is Serina Therapeutics in?
Serina Therapeutics’s primary industry is Drug Discovery.
-
Is Serina Therapeutics a private or public company?
Serina Therapeutics is a Public company.
-
What is Serina Therapeutics’s stock symbol?
The ticker symbol for Serina Therapeutics is SER.
-
What is the current stock price of Serina Therapeutics?
As of 13-Nov-2026 the stock price of Serina Therapeutics is $1.39.
-
What is the current market cap of Serina Therapeutics?
The current market capitalization of Serina Therapeutics is $36.9M.
-
What is Serina Therapeutics’s current revenue?
The trailing twelve month revenue for Serina Therapeutics is $125K.
-
Who are Serina Therapeutics’s competitors?
BeOne Medicines, Hansa Biopharma, AB Science, Cytovance Biologics, and GT Biopharma are some of the 60 competitors of Serina Therapeutics.
-
What is Serina Therapeutics’s annual earnings per share (EPS)?
Serina Therapeutics’s EPS for 12 months was -$1.63.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
